TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?

Tilray's fiscal 2026 revenue rose 11% to a record $915.5 million and adjusted EBITDA increased 11% to $61.1 million, but adjusted gross margin was flat at 29% and operating and adjusted free cash flow remained negative. Shares are down 54% year to date versus a 23% industry decline, while fiscal 2028 consensus EPS has deteriorated over 60 days from a $0.10 profit forecast to an $0.18 loss. Management guides fiscal 2027 adjusted EBITDA to $68-$75 million and targets an approximately $1.2 billion annualized revenue run rate, but dilution from an $87 million ATM raise, integration risk from BrewDog, competitive pressure and uncertain margin conversion support a wait-and-see stance.

Analysis

TLRY’s core issue is not demand but earnings quality: incremental revenue is increasingly sourced from distribution and acquired beverage assets, both likely lower-margin and working-capital-intensive than a scalable branded cannabis model. That mix can support reported growth while delaying free-cash-flow inflection; the balance-sheet benefit from low net debt is therefore partly offset by a recurring equity-financing risk if acquisition integration or working-capital conversion disappoints. Over the next 1-3 months, further estimate cuts are more likely than a valuation rerating absent evidence of positive operating cash flow.

The more investable European medical-cannabis angle may sit with ACB and CURA rather than TLRY. ACB’s narrower exposure offers greater sensitivity to high-margin medical volumes and any strategic bid premium, while CURA has larger-scale regulatory optionality; TLRY’s diversified platform reduces pure-play upside while embedding beverage execution risk. Germany reimbursement, wholesale pricing and import-license data are the key external checks: volume growth without price stabilization would validate that revenue expansion is not translating into economic profit.

Consensus may be overly focused on U.S. federal reform as a near-term catalyst. Regulatory progress could lift the entire cannabis complex within days, but it does not solve TLRY’s dilution and cash-conversion problem; a sector beta rally would be an opportunity to reduce or hedge TLRY unless management demonstrates sustained cash generation. For the next 6-18 months, the decisive KPI is whether acquired beverage operations and CC Pharma yield margin and working-capital improvement rather than merely a larger revenue base.

Key Decisions for Investors

• Maintain an underweight/short bias in TLRY on rallies over the next 1-3 months; use broad cannabis-sector strength or U.S. reform headlines as entry opportunities rather than chase weakness. Cover if the company reports two consecutive quarters of positive operating cash flow alongside EBITDA tracking above the upper end of guidance.
• Express relative European medical-cannabis strength via long ACB / short TLRY, sized beta-neutral, over a 3-6 month horizon. The thesis is falsified if ACB’s international gross-margin trajectory weakens materially or TLRY produces verified positive free cash flow without further equity issuance.
• Avoid treating CARL.B partnership exposure as a stand-alone TLRY catalyst until commercial terms, volumes and contribution margins are disclosed. Set an alert for disclosures showing beverage integration lifting consolidated gross margin rather than adding revenue with incremental working-capital needs.
• For event-driven cannabis exposure, prefer CURA over TLRY into U.S. regulatory milestones over 6-12 months; CURA offers more direct regulatory optionality, while TLRY retains higher execution and dilution sensitivity. Reduce exposure if federal action remains procedural rather than creating a concrete operating or capital-markets change.